EMA validates MAA for relugolix for the treatment of advanced prostate cancer – Myovant Sciences
Myovant Sciences announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for relugolix for the treatment of advanced prostate cancer. The validation of the… read more.
